Prediagnostic blood biomarkers for pancreatic cancer : meta-analysis
Pancreatic cancer is often detected at a late stage and usually leads to significant morbidity and deaths1. The 5-year survival rate for those with pancreatic cancer detected at a resectable stage is 25%, compared with a 5-year survival rate of 3% for those with pancreatic cancer that is not resectable2–4. Some 20% of patients have resectable disease at the time of diagnosis, underscoring the nece